Faron Pharmaceuticals Oy (GB:FARN) has released an update.
Faron Pharmaceuticals Oy has announced that Dr. Juho Jalkanen will take over as the new CEO, effective May 1, 2024, succeeding Dr. Markku Jalkanen, who will continue as a board member. Dr. Juho Jalkanen’s extensive experience within Faron, including his recent role as COO, his academic background, and previous medical practice, positions him to lead the company through upcoming milestones in the development of bexmarilimab, their leading immunotherapy drug.
For further insights into GB:FARN stock, check out TipRanks’ Stock Analysis page.
